Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis
Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.
generic viagra online
Strategies Evolving As Retractable Safety Syringe Suppliers Strive For Traction
Following the lead of the Needlestick Safety and Prevention Act in the U.S., government regulations regarding syringe needle handling and disposal continue to proliferate worldwide, fostering increased demand in the use of safety syringes. Retractable syringes represent the most elegant approach to addressing the caregiver sharps risk issue by lowering the risk of user error and de-emphasizing the need for a separate sharps disposal step.
News of the day
Short-Timer Whitehouse Has His Say
"While Sen. Sheldon Whitehouse (D-R.I.) is expected to be on the Senate Health, Education, Labor and Pensions Committee only for a short time, he should have a major effect on health reform," Roll Call reports. "Senate Majority Leader Harry Reid (D-Nev.) chose Whitehouse to temporarily take the place of former Sen. Hillary Rodham Clinton (D-N.Y.), now secretary of State, on HELP because of his experience with health care policy at the state level." But when Sen. Al Franken, D-Minn., takes over "the long-vacant Minnesota seat, Whitehouse"s time on the committee will soon be coming to an end -- but not before the health debate is finished."
Oncology

Global AIDS Coordinator Nominee Goosby Testifies Before Senate Committee

President Obama"s choice for the State Department"s global AIDS coordinator position, Eric Goosby, testified on Tuesday at a confirmation hearing with the Senate Foreign Relations Committee, VOA News reports. Goosby would work to continue PEPFAR"s success, and "says he will emphasize prevention if he is confirmed by the Senate," VOA News writes. Goosby, who is currently CEO of the Pangea Global AIDS Foundation and a professor of clinical medicine at the University of California in San Francisco, said, "My mission if confirmed will be to ensure that PEPFAR continues to be a visionary program, a program that continues to exceed our expectations of what can and should be provided to people in re-poor settings." He added, "Working closely with our global partners, we can help reclaim the lives of millions of people who would otherwise be lost to the infection." Senator Richard Lugar (R-Ind.) said that before PEPFAR began there were around 50,000 people in sub-Saharan Africa who were taking antiretroviral drugs. "Today, three times that many are being treated in Kenya alone," he said, adding that PEPFAR includes prevention programs that aim to halt 12 million new HIV cases. Senator Russ Feingold (D-Wisc.) who chaired the hearing said, "We cannot treat our way out of this pandemic alone. The numbers of infections continue to rise in some countries. We need to continue exploring and investing in new prevention strategies to stem the spread of HIV" (Tate, VOA news, 6/9). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009